Pancreatitis News and Research

RSS

Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors.

22 Sep 2009

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

PSC activation mechanisms help develop novel therapeutic approaches for pancreatic fibrosis

Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour. Pancreatic stellate cells (PSC) are the principal effector cells in pancreatic fibrosis. They are activated by profibrogenic mediators, which include, for example, cytokines and ethanol metabolites.

18 Sep 2009

Study to determine the outcomes and complications of ERCP in a community practice to appear in GIE journal

A new study from researchers in Minnesota found that endoscopic retrograde cholangiopancreatography (ERCP) performed in a community hospital setting results in complication rates that compare favorably with those of academic centers while achieving technical success at or above the performance levels recommended by the American Society for Gastrointestinal Endoscopy (ASGE)/American College of Gastroenterology (ACG) Task Force.

17 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Amsterdam Molecular Therapeutics reports 2009 half year financials

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

13 Aug 2009

Study could help target new pancreatitis treatments

Pancreatitis is often a fatal condition, in which the pancreas digests itself and surrounding tissue. Scientists have previously found that alcohol can trigger the condition by combining with fatty acids in the pancreas, which leads to an excessive release of stored calcium ions. Once calcium ions enter cell fluid in the pancreas it activates digestive enzymes and damages the cells.

29 Jun 2009

Early detection of pancreatic cancer closer thanks to multifunctional nanoparticles

Pancreatic cancer has a devastatingly low survival rate (less than 5 percent after 5 years) because it is usually diagnosed at an advanced stage. The initial symptoms, such as pain, jaundice, or weight loss, often do not allow the disease to be caught early enough for surgery and chemotherapy to be effective.

28 Jun 2009

Study redefines alcohol and smoking’s role in pancreatitis

Although alcohol consumption is known to be associated with chronic pancreatitis, new evidence indicates that a threshold of five or more drinks per day is required to significantly raise risk; however, most patients with chronic pancreatitis do not drink this amount, according to a report in the June 8 issue of Archives of Internal Medicine. In addition, smoking is an independent, dose-dependent risk factor.

9 Jun 2009

Toddler’s mysterious meningitis trumps cancer threat

Brooklynn Spencer's mother Samantha knew something wasn't right. The 8 month old had the flu recently, but it had been four weeks. She should have been better. The Elmira mother of four pushed for blood tests in early October 2007. A few hours later, there was a knock at the door.

21 May 2009

Amsterdam Molecular Therapeutics commences preregistration trial for Glybera

Amsterdam Molecular Therapeutics announced today the treatment of the first patient in a preregistration clinical trial with Glybera. This gene therapy product targets lipoprotein lipase deficiency (LPLD), a seriously debilitating and potentially lethal disease.

7 May 2009

Study examines radiation dose estimates for pregnant women undergoing therapeutic ERCP

Pregnant women with gallstone disease may require immediate endoscopic intervention because of potentially life-threatening cholangitis (infection in the bile ducts) or gallstone pancreatitis (inflammation of the pancreas).

30 Apr 2009

Thymoquinone inhibits the development of pancreatic cancer

An herb recently found to kill pancreatic cancer cells also appears to inhibit development of pancreatic cancer as a result of its anti-inflammatory properties, according to researchers from the Kimmel Cancer Center at Jefferson.

20 Apr 2009

Two or more alcoholic drinks a day may increase pancreatic cancer risk

Men and women who consume two or more alcoholic drinks a day could increase their risk of developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers and Prevention , a journal of the American Association for Cancer Research.

2 Apr 2009